Abstract: In accordance with the purpose(s) of the invention, as embodied and broadly described herein, the invention, in one aspect, relates to compounds comprising the structure: and at least one guanidinium residue, wherein m is zero or a positive integer. Also disclosed are methods of preparing the disclosed compounds. Also disclosed are methods of intracellular delivery comprising administering the disclosed compounds and compositions to a subject. Also disclosed are pharmaceutical compositions comprising a therapeutically effective amount of one or more compounds or compositions of the invention and a pharmaceutically acceptable carrier. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
Type:
Grant
Filed:
August 23, 2007
Date of Patent:
March 3, 2015
Assignee:
Vanderbilt University
Inventors:
Eva M. Harth, James E. Crowe, Jr., Kui Huang, Sharon K. Hamilton, Heidi E. Hamm, Bryan Voss
Abstract: This invention relates to DNA microarray technology, and more specifically to methods and kits for identifying autism and autism spectrum disorders in humans.
Abstract: A block copolymer comprising a methoxyethyl methacrylate (MOEMA) midblock is provided for forming a coating a medical device for controlled release of a bioactive agent.
Abstract: Provided are oligonucleotides that are capable of detecting KRAS and PIK3CA mutations in both cancer patients and healthy individuals with high specificity in kPCR assays. When the oligonucleotides are used as forward primers in conjunction with a defined genotyping algorithm spreadsheet, the primers are capable of enhancing detection of KRAS codon 12, 13, and 61 and PIK3CA codon 542, 545, and 1047 single nucleotide polymorphisms (SNPs) in a background of wild-type sequences. The oligonucleotides of the present invention are also capable of preventing pseudogene amplification when the oligonucleotides are hybridized as reverse primers or detection probes to the mismatch sequences.
Abstract: An antimicrobial composition comprises an anionic drug and an amine polymer comprising a first repeat unit of formula (2): wherein a? is an integer equal to 1 or 2, b? is an integer equal to 1 or 2, and each R? is an independent monovalent radical selected from the group consisting of hydrogen, methyl, ethyl, and combinations thereof. G? is a divalent linking group selected from the group consisting of a single bond and groups comprising at least one carbon. X? is a negatively charged counterion. The drug and the amine polymer are bound by noncovalent interactions.
Type:
Grant
Filed:
September 12, 2012
Date of Patent:
January 6, 2015
Assignees:
International Business Machines Corporation, Agency For Science, Technology And Research
Inventors:
James L. Hedrick, Shrinivas Venkataraman, Yi Yan Yang
Abstract: Methods for detecting the presence or amount of Johnsongrass or Johnsongrass hybrid genetic material in a biological sample, preferably the detection of the presence or amount of Johnsongrass or Johnsongrass hybrid seed in a seed sample, are disclosed. The methods involve detection of certain nucleic acid sequences, namely Johnsongrass detection sequences, optionally through a primer-based amplification process, such as PCR. Also disclosed are isolated polynucleotides, replication compositions and kits for carrying out the detection methods.
Type:
Grant
Filed:
April 26, 2011
Date of Patent:
December 16, 2014
Assignee:
Pioneer Hi Bred International Inc
Inventors:
Benjamin Kaufman, Mulu Ayele, Olga Ellern
Abstract: Hyaluronic acid (HA) conjugates or crosslinked HAs compositions for coating an implantable device are provided. The implantable device can be used for treating a disorder such as atherosclerosis, thrombosis, restenosis, high cholesterol, hemorrhage, vascular dissection or perforation, vascular aneurysm, vulnerable plaque, chronic total occlusion, claudication, anastomotic proliferation for vein and artificial grafts, bile duct obstruction, ureter obstruction, tumor obstruction, and combinations thereof.
Type:
Grant
Filed:
September 28, 2012
Date of Patent:
December 9, 2014
Assignee:
Advanced Cardiovascular Systems, Inc.
Inventors:
Syed Faiyaz Ahmed Hossainy, Eugene Michal, Thierry Glauser, Connie Kwok, Stephen Dirk Pacetti
Abstract: The invention relates to methods and compositions for identifying and for selecting maize plants with mechanical stalk strength characteristics. The methods use molecular markers to identify and select plants with increased mechanical stalk strength or to identify and counter-select plants with decreased mechanical stalk strength. Maize plants generated by the methods of the invention are also a feature of the invention.
Type:
Grant
Filed:
July 14, 2009
Date of Patent:
December 2, 2014
Assignee:
E.I. du Pont de Nemours and Company
Inventors:
Ada Ching, J. Antoni Rafalski, Stanley Luck, Marymar Goncalves Butruille
Abstract: The present application discloses biodegradable polymers, to porous and other materials comprising such polymers, and to various medical uses of such materials, including use as a scaffold for supporting cell adhesion or the in-growth for regeneration of tissue. The polymer is of the formula A-O—(CHR1CHR2O)n—B wherein A is a poly(lactide-co-glycolide) residue, the molar ratio of (i) lactide units [—CH(CH3)—COO—] and (ii) glycolide units [—CH2—COO—] in the poly(lactide-co-glycolide) residue being in the range of 80:20 to 10:90, B is either a poly(lactide-co-glycolide) residue or hydrogen, C1-6-alkyl or hydroxy protecting groups, one of R1 and R2 is hydrogen or methyl, and the other is hydrogen, n is 10-1000, the molar ratio of (iii) polyalkylene glycol units [—(CHR1CHR2O)—] to the combined amount of (i) lactide units and (ii) glycolide units in the poly(lactide-co-glycolide) residue(s) is at the most 14:86, and the molecular weight of the copolymer is at least 20,000 g/mol.
Type:
Grant
Filed:
March 7, 2007
Date of Patent:
November 4, 2014
Assignee:
Coloplast A/S
Inventors:
Jakob Vange, Khadija Schwach-Abdellaoui, Hanne Everland, Peter Sylvest Nielsen, Brian Nielsen, Lene Karin Jespersen, Lene Feldskov Nielsen
Abstract: Hyaluronic acid (HA) conjugates or crosslinked HAs compositions for coating an implantable device are provided. The implantable device can be used for treating a disorder such as atherosclerosis, thrombosis, restenosis, high cholesterol, hemorrhage, vascular dissection or perforation, vascular aneurysm, vulnerable plaque, chronic total occlusion, claudication, anastomotic proliferation for vein and artificial grafts, bile duct obstruction, ureter obstruction, tumor obstruction, and combinations thereof.
Type:
Grant
Filed:
September 28, 2012
Date of Patent:
September 30, 2014
Assignee:
Advanced Cardiovascular Systems, Inc.
Inventors:
Thierry Glauser, Syed Faiyaz Ahmed Hossainy, Connie Kwok, Stephen Dirk Pacetti, Eugene Michal
Abstract: Silane-functionalized hydrophobic ?(1?4)glucopyranose polymers and polymeric matrices are described. Biodegradable matrices can be formed from hydrophobic ?(1?4)glucopyranose polymers with reactive pendent silyl ether groups. Reaction of the silyl ether groups provides improved matrix formation through bonding to a device surface of a device, polymer-polymer crosslinking, or both. Biodegradable matrices can be used for the preparation of implantable and injectable medical devices, including those that release a bioactive agent.
Type:
Grant
Filed:
June 2, 2010
Date of Patent:
August 12, 2014
Assignee:
Surmodics, Inc.
Inventors:
Aleksey V. Kurdyumov, Nathan A. Lockwood, Joram Slager, Dale G. Swan, Robert Hergenrother
Abstract: Identified herein are different forms of sweet and umami receptor encoding sequences that occur in different human populations. In particular, there are provided several single nucleotide polymorphisms (SNPs) that occur within the exons/coding sequence (and are therefore coding SNPs, cSNPs) of one of the three T1R genes. Some SNPs cause amino acid substitutions, while others introduce a chain termination codon, rendering a truncated product. Differences in these genes are believed to affect the sense of taste of individuals, such that individuals with different SNPs (or different haplotypes) are believed to perceive the taste of sweet or umami (e.g., glutamate) substances differently than the rest of the population. The ability to assay this allelic information is useful in the development of flavorings and flavor enhancers, as it can be used to define groups and populations who perceive tastes differently. This in turn allows the taste preferences of these groups to be addressed at the molecular level.
Type:
Grant
Filed:
April 13, 2006
Date of Patent:
August 5, 2014
Assignee:
The United States of America as represented by the Secretary of the Department of Health and Human Services
Abstract: An implant for insertion into a punctum of a patient comprises a body. The body has a distal end, a proximal end, and an axis therebetween. The distal end of the body is insertable distally through the punctum into the canalicular lumen. The body comprises a therapeutic agent included within an agent matrix drug core. Exposure of the agent matrix to the tear fluid effects an effective therapeutic agent release into the tear fluid over a sustained period. The body has a sheath disposed over the agent matrix to inhibit release of the agent away from the proximal end. The body also has an outer surface configured to engage luminal wall tissues so as to inhibit expulsion when disposed therein. In specific embodiments, the agent matrix comprises a non-bioabsorbable polymer, for example silicone in a non-homogenous mixture with the agent.
Type:
Grant
Filed:
April 2, 2007
Date of Patent:
August 5, 2014
Assignee:
Mati Therapeutics Inc.
Inventors:
Eugene de Juan, Jr., Cary Reich, Stephen Boyd, Hanson G. Gifford, III, Mark Deem
Abstract: Disclosed is a novel device for the vacuum infusion of a porous medical implant contained therein with one or more pharmaceutical substances and a method for the device's use. The device is deformable, and capable of adjusting to the outer contour of a porous medical implant to facilitate packaging, shipping and storage of the implant contained within the device. In addition, the device is unbreakable, easily disposed of after use, maintains the implant in a sterile condition before and after infusion and minimizes the quantity of pharmaceutical substance needed for infusion. Use of the device provides for rapid and complete infusion of a variety of pharmaceutical substances into a porous implant prior to surgery.
Abstract: Methods for detecting cancer that include hybridizing a set of chromosomal probes to a biological sample obtained from a patient, and identifying if aneusomic cells are present in a selected subset of cells obtained from the biological sample are described. A set of chromosomal probes and kits for detecting cancer that include sets of chromosomal probes, are also described.
Type:
Grant
Filed:
May 13, 2013
Date of Patent:
July 22, 2014
Assignees:
Mayo Foundation for Medical Education and Research, Abbott Molecular Inc.
Inventors:
Kevin C. Halling, Robert B. Jenkins, Walter King, Irina A. Sokolova, Steven A. Seelig
Abstract: The invention comprises a transdermal dosage form comprising an active agent component comprising an active agent and an adverse agent component comprising an adverse agent, wherein the active agent component defines at least one channel extending substantially there through.
Abstract: The present invention relates to methods and compositions for identifying biomarkers that indicate a biological state, in particular cancer or predisposition to cancer.
Type:
Grant
Filed:
March 30, 2009
Date of Patent:
July 8, 2014
Assignee:
The University of Toledo
Inventors:
James C. Willey, Thomas M. Blomquist, Erin L. Crawford, D'Anna N. Mullins
Abstract: The present disclosure relates to methods and compositions for identifying biomarkers that indicate a biological state, in particular cancer or predisposition to cancer. Also provided are methods and compositions for identifying a greater risk for a cancer-related condition in an subject.
Type:
Grant
Filed:
September 17, 2008
Date of Patent:
July 1, 2014
Assignee:
The University of Toledo
Inventors:
James C. Willey, Thomas M. Blomquist, Erin L. Crawford, D'Anna N. Mullins
Abstract: This invention is directed to methods, kits, non-nucleotide probes as well as other compositions pertaining to the suppression of binding of detectable nucleic acid probes to undesired nucleotide sequences of genomic nucleic acid in assays designed to determine target genomic nucleic acid.
Type:
Grant
Filed:
February 8, 2012
Date of Patent:
June 17, 2014
Assignees:
Boston Probes, Inc., Dako Denmark A/S
Inventors:
Kirsten Vang Nielsen, Jens J. Hyldig-Nielsen, Brett F. Williams
Abstract: The present invention is directed to unsaturated sphingosine compounds which are useful as therapeutic agents for the treatment of cancer and for the treatment of other diseases including diabetes and infection with intracellular bacteria. This invention is also directed to methods of using the compounds and pharmaceutical compositions comprising the compounds in treating these diseases.
Type:
Grant
Filed:
December 12, 2008
Date of Patent:
June 3, 2014
Assignees:
Children's Hospital & Research Center at Oakland, Research Foundation of the City University of New York
Inventors:
Julie D. Saba, Henrik Fyrst, Robert Bittman